Sugi Predict

Sugi Predict / Compounds / SCHEMBL2103070

SCHEMBL2103070

SCHEMBL2103070

CS(=O)(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 3/20 0.72
▸ CYP1A2 P05177 1/20 0.65
▸ CYP2D6 P10635 1/20 0.65
▸ HIF1A Q16665 1/20 0.65
▸ SMN1; SMN2 Q16637 5/20 0.61
▸ MEN1 O00255 3/20 0.61
▸ KMT2A Q03164 3/20 0.61
▸ MAPT P10636 2/20 0.61
▸ NPC1 O15118 1/20 0.61
▸ RAB9A P51151 1/20 0.61
▸ ALDH1A1 P00352 4/20 0.59
▸ POLB P06746 1/20 0.57
▸ HPGD P15428 2/20 0.56
▸ TSHR P16473 1/20 0.56
▸ PKM P14618 1/20 0.55
▸ USP2 O75604 2/20 0.55
▸ CYP2C19 P33261 2/20 0.55
▸ HSD17B10 Q99714 2/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ LMNA P02545 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2155130 0.89 SMN1; SMN2 (0.68) CYP2C9CYP1A2CYP2D6HIF1ASMN1; SMN2
SCHEMBL5916444 0.85 SMN1; SMN2 (0.56) CYP2C9CYP1A2CYP2D6HIF1ASMN1; SMN2
SCHEMBL2155221 0.85 MAPT (0.58) CYP2C9CYP1A2CYP2D6HIF1ASMN1; SMN2
SCHEMBL19634850 0.82 KMT2A (0.64) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL82680 0.82 MEN1 (0.69) CYP2C9SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL2959258 0.82 ALDH1A1 (0.57) CYP2C9MEN1KMT2AMAPTALDH1A1
SCHEMBL20004452 0.81 POLB (0.54) CYP2C9CYP1A2CYP2D6SMN1; SMN2MEN1
SCHEMBL974007 0.81 POLB (0.54) CYP2C9CYP1A2CYP2D6SMN1; SMN2MEN1
SCHEMBL1926789 0.81 MAPT (0.58) CYP2C9CYP1A2CYP2D6SMN1; SMN2MEN1
SCHEMBL6152910 0.81 MAPT (0.58) CYP2C9CYP1A2CYP2D6SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3458459-B1 MACROCYCLIC INDOLE DERIVATIVES BAYER AG (DE) 2022-04-27 — — EP disclosed
EP-3209664-B1 BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-06-03 — — EP disclosed
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 — — US disclosed
EP-2758398-B1 SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL]-2-AZABICYCLO [2.2.1]HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C BOEHRINGER INGELHEIM INT (DE) 2017-08-02 — — EP disclosed
US-20160368918-A1 SYK INHIBITORS Kronos Bio, Inc. 2016-12-22 — — US disclosed
US-20160368918-A1 SYK INHIBITORS Kronos Bio, Inc. 2016-12-22 — — US disclosed
US-9376441-B2 Substituted pyrrolidines as SYK inhibitors GILEAD SCIENCES, INC. (US) 2016-06-28 — — US disclosed
US-9376441-B2 Substituted pyrrolidines as SYK inhibitors GILEAD SCIENCES, INC. (US) 2016-06-28 — — US disclosed
US-20150260889-A1 NEAR-INFRARED CUT FILTER ASAHI GLASS COMPANY, LIMITED (JP) 2015-09-17 — — US disclosed
US-20150260889-A1 NEAR-INFRARED CUT FILTER ASAHI GLASS COMPANY, LIMITED (JP) 2015-09-17 — — US disclosed
US-20090233909-A1 Sulfonamide compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2009-09-17 — — US disclosed
CN-101252929-A G protein-coupled receptor agonists PROSIDION LTD (GB) 2008-08-27 — — CN disclosed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 — — US disclosed
CN-101124213-A Sulfonylamino cyclic derivatives and uses thereof SERONO LAB (CH) 2008-02-13 — — CN disclosed
EP-1828160-A1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS LABORATOIRES SERONO S.A. (CH) 2007-09-05 — — EP disclosed
WO-2006067114-A1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2006-06-29 — — WO disclosed
EP-0408714-B1 HETEROCYCLIC SULPHONYLNITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS ICI PLC (GB) 1994-01-26 — — EP disclosed
US-5096918-A Aldose reductase inhibitors, diabetes, galactosemia IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-03-17 — — US disclosed
EP-0408714-A1 HETEROCYCLIC SULPHONYLNITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS. ICI PLC (GB) 1991-01-23 — — EP disclosed
WO-1990008762-A1 HETEROCYCLIC SULPHONYLNITROMETANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233909-A1 Sulfonamide compounds as cysteine protease inhibitors CTSF, CTSS, CSTB CYP2C9 702/4885CYP1A2 1791/4885CYP2D6 435/4885
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof GLS2, SRM, GLS CYP2C9 613/4885CYP1A2 1229/4885CYP2D6 2369/4885
US-20160368918-A1 SYK INHIBITORS SYK, BTK, LYN CYP2C9 3298/4885CYP1A2 3603/4885CYP2D6 3089/4885
US-10005774-B2 Syk inhibitors SYK, BTK, LYN CYP2C9 3298/4885CYP1A2 3603/4885CYP2D6 3089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.